SCHEMBL15325934

SCHEMBL15325934

COC(=O)c1ccc(-c2nc(CS(=O)(=O)[C@H]3CC[C@@H](NC(=O)OC(C)(C)C)CC3)c(C)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.47
MEN1 O00255 3/20 0.47
HRH1 P35367 1/20 0.45
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15325984 1.00 KMT2A (0.47) KMT2AMEN1HRH1HSD17B10KDM4E
SCHEMBL12469068 1.00 KMT2A (0.47) KMT2AMEN1HRH1HSD17B10KDM4E
SCHEMBL15419606 0.95 KMT2A (0.44) KMT2AMEN1HRH1HSD17B10KDM4E
SCHEMBL15419485 0.95 KMT2A (0.44) KMT2AMEN1HRH1HSD17B10KDM4E
SCHEMBL15325978 0.92 KMT2A (0.48) KMT2AMEN1HSD17B10KDM4ETP53
SCHEMBL15326071 0.92 KMT2A (0.48) KMT2AMEN1HSD17B10KDM4ETP53
SCHEMBL12469507 0.92 KMT2A (0.48) KMT2AMEN1HSD17B10KDM4ETP53
SCHEMBL15325933 0.90 KMT2A (0.47) KMT2AMEN1HSD17B10KDM4ETP53
SCHEMBL15419564 0.87 KMT2A (0.45) KMT2AMEN1HSD17B10KDM4ETP53
SCHEMBL15419500 0.87 KMT2A (0.45) KMT2AMEN1HSD17B10KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 US disclosed
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 US disclosed
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES ARAVIVE BIOLOGICS, INC. 2015-03-12 US disclosed
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES ARAVIVE BIOLOGICS, INC. 2015-03-12 US disclosed
US-20140024649-A1 Substituted Benzamides and Their Uses AUCKLAND UNISERVICES LIMITED (NZ) 2014-01-23 US disclosed
US-20140024649-A1 Substituted Benzamides and Their Uses AUCKLAND UNISERVICES LIMITED (NZ) 2014-01-23 US disclosed
WO-2013155338-A2 SUBSTITUTED BENZAMIDES AND THEIR USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA KMT2A 459/4885MEN1 2797/4885HRH1 1281/4885
US-20140024649-A1 Substituted Benzamides and Their Uses NISCH, BTD, NAAA KMT2A 459/4885MEN1 2797/4885HRH1 1281/4885
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA KMT2A 459/4885MEN1 2797/4885HRH1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.